The Financial Times shared a great history of the ups and downs of GW Pharma (NASDAQ: GWPH), which will soon report the results of the first of four Phase 3 FDA clinical trials for its potential blockbuster drug for epilepsy, Epidiolex. The article discusses the shrewd move a few years ago to list its shares on the NASDAQ, which gave the company better access to capital. CEO Justin Gover has moved to the U.S. subsequently.
This is what we’ve been working towards for 16 years. I’m excited but I wouldn’t be human if I didn’t have some nerves.
Justin Gover, CEO
Read Andrew Ward’s “Decisive moment looms for UK maker of medical marijuana”: http://www.ft.com/cms/s/0/39db3e7a-bab8-11e5-bf7e-8a339b6f2164.html#axzz3yvDvIAns
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.